Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

September 01, 1984; Volume 26,Issue 2
  • You have access
    Relationships between phosphoinositide and calcium responses to muscarinic agonists in astrocytoma cells.
    S B Masters, T K Harden and J H Brown
    Molecular Pharmacology September 1984, 26 (2) 149-155;
  • You have access
    Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115). Selective loss with subculturing of the low-affinity agonist site mediating cyclic GMP formation.
    M McKinney, S Stenstrom and E Richelson
    Molecular Pharmacology September 1984, 26 (2) 156-163;
  • You have access
    [3H]Pirenzepine and [3H]quinuclidinyl benzilate binding to brain muscarinic cholinergic receptors. Differences in measured receptor density are not explained by differences in receptor isomerization.
    G R Luthin and B B Wolfe
    Molecular Pharmacology September 1984, 26 (2) 164-169;
  • You have access
    The conversion of 2-chloroalkylamine analogues of oxotremorine to aziridinium ions and their interactions with muscarinic receptors in the guinea pig ileum.
    B Ringdahl, B Resul, F J Ehlert, D J Jenden and R Dahlbom
    Molecular Pharmacology September 1984, 26 (2) 170-179;
  • You have access
    Hormonal inhibition of adenylate cyclase. A crucial role for Mg2+.
    J Bockaert, B Cantau and M Sebben-Perez
    Molecular Pharmacology September 1984, 26 (2) 180-186;
  • You have access
    Photoaffinity cross-linking of a radioiodinated probe, 125I-A55453, into alpha 1-adrenergic receptors.
    K E Dickinson, L M Leeb-Lundberg, S L Heald, J E Wikberg, J F DeBernardis, M G Caron and R J Lefkowitz
    Molecular Pharmacology September 1984, 26 (2) 187-195;
  • You have access
    Alpha 1-adrenergic receptor structure.
    J C Venter, P Horne, B Eddy, R Greguski and C M Fraser
    Molecular Pharmacology September 1984, 26 (2) 196-205;
  • You have access
    Desensitization of catecholamine-stimulated adenylate cyclase and down-regulation of beta-adrenergic receptors in rat glioma C6 cells. Role of cyclic AMP and protein synthesis.
    T G Zaremba and P H Fishman
    Molecular Pharmacology September 1984, 26 (2) 206-213;
  • You have access
    The ternary complex model. Its properties and application to ligand interactions with the D2-dopamine receptor of the anterior pituitary gland.
    K A Wreggett and A De Léan
    Molecular Pharmacology September 1984, 26 (2) 214-227;
  • You have access
    Kinetic differences between type I and type II benzodiazepine receptors.
    R R Trifiletti, M M Lo and S H Snyder
    Molecular Pharmacology September 1984, 26 (2) 228-240;
  • You have access
    Evidence for two molecular forms of solubilized vasopressin receptors in rat kidney membranes. Regulation by guanyl nucleotides.
    G Guillon, D Butlen and R Rajerison
    Molecular Pharmacology September 1984, 26 (2) 241-247;
  • You have access
    A new type of tachykinin binding site in the rat brain characterized by specific binding of a labeled eledoisin derivative.
    J C Beaujouan, Y Torrens, A Viger and J Glowinski
    Molecular Pharmacology September 1984, 26 (2) 248-254;
  • You have access
    Enkephalin biosynthesis in adrenal medulla. Modulation of proenkephalin mRNA content of cultured chromaffin cells by 8-bromo-adenosine 3',5'-monophosphate.
    T T Quach, F Tang, H Kageyama, I Mocchetti, A Guidotti, J L Meek, E Costa and J P Schwartz
    Molecular Pharmacology September 1984, 26 (2) 255-260;
  • You have access
    Phorbol ester-induced protein secretion in rat parotid gland. Relationship to the role of inositol lipid breakdown and protein kinase C activation in stimulus-secretion coupling.
    J W Putney, J S McKinney, D L Aub and B A Leslie
    Molecular Pharmacology September 1984, 26 (2) 261-266;
  • You have access
    Influence of a tumor-promoting phorbol ester on the electrical response of B-cells to glucose and glyburide.
    C S Pace
    Molecular Pharmacology September 1984, 26 (2) 267-271;
  • You have access
    Factors influencing the covalent binding of (+/-)-7 beta, 8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene to ribonucleic acids.
    T H Zytkovicz and C D Liarakos
    Molecular Pharmacology September 1984, 26 (2) 269-275;
  • You have access
    Structural requirements for the pharmacological activity of nonsteroidal antiestrogens in vitro.
    V C Jordan, M E Lieberman, E Cormier, R Koch, J R Bagley and P C Ruenitz
    Molecular Pharmacology September 1984, 26 (2) 272-278;
  • You have access
    Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure.
    V C Jordan and M E Lieberman
    Molecular Pharmacology September 1984, 26 (2) 279-285;
  • You have access
    Effects of calmodulin antagonists on immune mouse lymphocytes.
    G Wolberg and T P Zimmerman
    Molecular Pharmacology September 1984, 26 (2) 286-292;
  • You have access
    Interactions of bupivacaine with ionic channels of the nicotinic receptor. Electrophysiological and biochemical studies.
    S R Ikeda, R S Aronstam, J W Daly, Y Aracava and E X Albuquerque
    Molecular Pharmacology September 1984, 26 (2) 293-303;
  • You have access
    Interactions of bupivacaine with ionic channels of the nicotinic receptor. Analysis of single-channel currents.
    Y Aracava, S R Ikeda, J W Daly, N Brookes and E X Albuquerque
    Molecular Pharmacology September 1984, 26 (2) 304-313;
  • You have access
    The influence of local anesthetics on molecular organization in phosphatidylethanolamine membranes.
    E C Kelusky and I C Smith
    Molecular Pharmacology September 1984, 26 (2) 314-321;
  • You have access
    In vitro studies on the distribution of probucol among human plasma lipoproteins.
    S Urien, P Riant, E Albengres, R Brioude and J P Tillement
    Molecular Pharmacology September 1984, 26 (2) 322-327;
  • You have access
    Mechanism of the stimulation of prostaglandin H synthase and prostacyclin synthase by the antithrombotic and antimetastatic agent, nafazatrom.
    L J Marnett, P H Siedlik, R C Ochs, W R Pagels, M Das, K V Honn, R H Warnock, B E Tainer and T E Eling
    Molecular Pharmacology September 1984, 26 (2) 328-335;
  • You have access
    Studies on porphyrin metabolism in the kidney. Effects of trace metals and glutathione on renal uroporphyrinogen decarboxylase.
    J S Woods, D L Eaton and C B Lukens
    Molecular Pharmacology September 1984, 26 (2) 336-341;
  • You have access
    Reaction of mutagenic phenacetin metabolites with glutathione and DNA. Possible implications for toxicity.
    G J Mulder, F F Kadlubar, J B Mays and J A Hinson
    Molecular Pharmacology September 1984, 26 (2) 342-347;
  • You have access
    Hydroperoxyflavin-mediated oxidations of organosulfur compounds. Model studies for the flavin monooxygenase.
    D R Doerge and M D Corbett
    Molecular Pharmacology September 1984, 26 (2) 348-352;
  • You have access
    Carcinogen-binding proteins. High-affinity binding sites for benzo[a]pyrene in mouse liver distinct from the Ah receptor.
    S Collins and M A Marletta
    Molecular Pharmacology September 1984, 26 (2) 353-359;
  • You have access
    Mechanism of HgCl2 cytotoxicity in cultured mammalian cells.
    O Cantoni, N T Christie, A Swann, D B Drath and M Costa
    Molecular Pharmacology September 1984, 26 (2) 360-368;
  • You have access
    Comparative inhibition of DNA polymerases from varicella zoster virus (TK+ and TK-) strains by (E)-5-(2-bromovinyl)-2'-deoxyuridine 5'-triphosphate.
    T Yokota, K Konno, S Shigeta and E De Clercq
    Molecular Pharmacology September 1984, 26 (2) 376-380;
  • You have access
    1-beta-D-arabinosyl-5-azacytosine. Cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells.
    R I Glazer and M C Knode
    Molecular Pharmacology September 1984, 26 (2) 381-387;
  • You have access
    Analytical DNA flow cytometric analysis of deoxyadenosine toxicity in cultured human leukemic lymphoblasts.
    R M Fox, E H Tripp and I W Taylor
    Molecular Pharmacology September 1984, 26 (2) 388-394;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 26, Issue 2
1 Sep 1984
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics